 results addition interferon treatment patients metastatic malignant melanoma Sixty-four patients metastatic malignant melanoma trial Patients dacarbazine DTIC DTIC interferon IFN Patients respect age sex performance status PS site metastases number metastatic sites Objective response complete partial remission CR PR patients DTIC patients DTIC IFN Median time treatment failure TTF median survival combination arm long-term CRs toxicity combination arm acceptable patients treatment IFN toxicity